130 related articles for article (PubMed ID: 33596143)
21. Claspin overexpression is associated with high-grade histology and poor prognosis in renal cell carcinoma.
Kobayashi G; Sentani K; Babasaki T; Sekino Y; Shigematsu Y; Hayashi T; Oue N; Teishima J; Matsubara A; Sasaki N; Yasui W
Cancer Sci; 2020 Mar; 111(3):1020-1027. PubMed ID: 31912588
[TBL] [Abstract][Full Text] [Related]
22. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
23. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
25. Bax-interacting factor-1 inhibits cell proliferation and promotes apoptosis in prostate cancer cells.
Xu L; Wang Z; He SY; Zhang SF; Luo HJ; Zhou K; Li XF; Qiu SP; Cao KY
Oncol Rep; 2016 Dec; 36(6):3513-3521. PubMed ID: 27748942
[TBL] [Abstract][Full Text] [Related]
26. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of serum CXCL4L1 predicts progression and poor prognosis in prostate cancer patients treated by radical prostatectomy.
Zhang M; Guan J; Huo YL; Song YS; Chen LZ
Asian J Androl; 2019; 21(4):387-392. PubMed ID: 30860083
[TBL] [Abstract][Full Text] [Related]
28. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
[TBL] [Abstract][Full Text] [Related]
29. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer.
Wan Y; Zeng ZC; Xi M; Wan S; Hua W; Liu YL; Zhou YL; Luo HW; Jiang FN; Zhong WD
Hum Pathol; 2015 Feb; 46(2):295-303. PubMed ID: 25532941
[TBL] [Abstract][Full Text] [Related]
30. Up-regulation of LIMK1 expression in prostate cancer is correlated with poor pathological features, lymph node metastases and biochemical recurrence.
Huang JB; Wu YP; Lin YZ; Cai H; Chen SH; Sun XL; Li XD; Wei Y; Zheng QS; Xu N; Xue XY
J Cell Mol Med; 2020 Apr; 24(8):4698-4706. PubMed ID: 32168432
[TBL] [Abstract][Full Text] [Related]
31. A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival.
Huang TB; Dong CP; Zhou GC; Lu SM; Luan Y; Gu X; Liu L; Ding XF
Int Urol Nephrol; 2017 May; 49(5):825-835. PubMed ID: 28188414
[TBL] [Abstract][Full Text] [Related]
32. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
33. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1.
Lin ZY; Huang YQ; Zhang YQ; Han ZD; He HC; Ling XH; Fu X; Dai QS; Cai C; Chen JH; Liang YX; Jiang FN; Zhong WD; Wang F; Wu CL
Int J Cancer; 2014 Aug; 135(3):541-50. PubMed ID: 24382668
[TBL] [Abstract][Full Text] [Related]
35. Decreased HoxD10 Expression Promotes a Proliferative and Aggressive Phenotype in Prostate Cancer.
Mo RJ; Lu JM; Wan YP; Hua W; Liang YX; Zhuo YJ; Kuang QW; Liu YL; He HC; Zhong WD
Curr Mol Med; 2017; 17(1):70-78. PubMed ID: 28231752
[TBL] [Abstract][Full Text] [Related]
36. UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy.
Wan X; Yang S; Huang W; Wu D; Chen H; Wu M; Li J; Li T; Li Y
J Exp Clin Cancer Res; 2016 Feb; 35():34. PubMed ID: 26884069
[TBL] [Abstract][Full Text] [Related]
37. Decreased Expression of MYPT1 Contributes to Tumor Angiogenesis and Poor Patient Prognosis in Human Prostate Cancer.
Liang Y; Zhuo Y; Lin Z; Jiang F; Dai Q; Lu J; Dong W; Zhu X; Han Z; Zhong W
Curr Mol Med; 2018; 18(2):100-108. PubMed ID: 29974831
[TBL] [Abstract][Full Text] [Related]
38. The EEF1A2 gene expression as risk predictor in localized prostate cancer.
Worst TS; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Steidler A; von Hardenberg J; Michel MS; Erben P
BMC Urol; 2017 Sep; 17(1):86. PubMed ID: 28923030
[TBL] [Abstract][Full Text] [Related]
39. miR-196a-mediated downregulation of p27
Zhan B; Huang L; Chen Y; Ye W; Li J; Chen J; Yang S; Jiang W
Prostate; 2020 Sep; 80(12):1024-1037. PubMed ID: 32628792
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]